論文

査読有り
2019年9月25日

Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial.

Circulation journal : official journal of the Japanese Circulation Society
  • Junya Ako
  • ,
  • Kiyoshi Hibi
  • ,
  • Kenichi Tsujita
  • ,
  • Takafumi Hiro
  • ,
  • Yoshihiro Morino
  • ,
  • Ken Kozuma
  • ,
  • Toshiro Shinke
  • ,
  • Hiromasa Otake
  • ,
  • Kiyoko Uno
  • ,
  • Michael J Louie
  • ,
  • Yoshiharu Takagi
  • ,
  • Katsumi Miyauchi

83
10
開始ページ
2025
終了ページ
2033
記述言語
英語
掲載種別
DOI
10.1253/circj.CJ-19-0412

BACKGROUND: In patients with acute coronary syndrome (ACS), alirocumab reduced the risk of recurring ischemic events. ODYSSEY J-IVUS assessed the effect of alirocumab on coronary atheroma volume in Japanese patients recently hospitalized with ACS and hypercholesterolemia, using intravascular ultrasound imaging analysis.Methods and Results:Patients (n=206) who at index ACS diagnosis either had low-density lipoprotein cholesterol (LDL-C) ≥2.59 mmol/L (≥100 mg/dL) despite stable statin therapy, or were not on statins with LDL-C levels above target after statin initiation, were randomized (1:1) to alirocumab (75 mg every 2 weeks [Q2 W]/up to 150 mg Q2 W), or standard of care (SoC; atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day) for 36 weeks. The primary efficacy endpoint (week [W] 36 mean [standard error] percent change in normalized total atheroma volume [TAV] from baseline) was -3.1 (1.0)% with SoC vs. -4.8 (1.0)% with alirocumab (between-group difference: -1.6 [1.4]; P=0.23). W36 absolute change from baseline in percent atheroma volume was -1.3 (0.4)% (SoC) and -1.4 (0.4)% (alirocumab; nominal P=0.79). At W36, LDL-C was reduced from baseline by 13.4% (SoC) vs. 63.9% (alirocumab; nominal P<0.0001). In total, 61.8% (SoC) and 75.7% (alirocumab) of patients reported treatment-emergency adverse events. CONCLUSIONS: In Japanese patients with ACS and hypercholesterolemia inadequately controlled despite statin therapy, from baseline to W36, a numerically greater percent reduction in normalized TAV was observed with alirocumab vs. SoC, which did not reach statistical significance.

Web of Science ® 被引用回数 : 3

リンク情報
DOI
https://doi.org/10.1253/circj.CJ-19-0412
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/31434809
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000487717600010&DestApp=WOS_CPL

エクスポート
BibTeX RIS